What amount sold does Sparrow Pharmaceuticals, Inc. report in Form D filings?

The latest linked filings report $73.3M sold across 4 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Sparrow Pharmaceuticals, Inc.'s most recent SEC filing?

Sparrow Pharmaceuticals, Inc.'s most recent Form D filing was on 2025-07-01.

How many investors does Sparrow Pharmaceuticals, Inc. have?

The most recent Form D filing lists 17 investor(s).

What type of securities does Sparrow Pharmaceuticals, Inc. offer?

Sparrow Pharmaceuticals, Inc.'s SEC Form D filings indicate equity offerings.

Sparrow Pharmaceuticals, Inc.

CIK: 0001786949·Pharmaceuticals·PORTLAND, OR·Corporation

Reported Sold

$73,253,980

Total Filings

Identified Offerings

Last Filed

Jul 1, 2025

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Pharmaceuticals industry

SEC EDGAR

Offering filing timeline

Jul 1, 2025Form D — New notice

Reported sold: $61,841,225 · Target: $121,400,027

Rule 506(b)·17 investors

Apr 12, 2024Form D — New notice

Reported sold: $10,000,000 · Target: $15,251,730

Rule 506(b)·4 investors

Jan 13, 2021Form D — New notice

Reported sold: $1,075,255 · Target: $50,825,257

Rule 506(b)·15 investors

Jun 26, 2020Form D/A — Amendment

Reported sold: $337,500 · Target: $337,500

Rule 506(b)·10 investors

Changed: Reported amount sold, Offering target, Sales commissions

Nov 15, 2019Form D — New notice

Reported sold: $270,000 · Target: $8,000,000

Rule 506(b)·10 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

$675

Amendment Rate

20%

Latest reported sold across 4 identified offerings

$73,253,980

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Robert Jacks

Related Person

Appears on 3 filings

Peter Thompson

Related Person

Appears on 3 filings

Klaus Veitinger

Related Person

Appears on 3 filings

David Aaron Katz

Related Person

Appears on 2 filings

Jonathan Root

Related Person

Appears on 2 filings

Niall O'Donnell

Related Person

Appears on 2 filings

David Katz

Related Person

Appears on 1 filing

Nanna L?neborg

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Jul 1, 2025	New	$121,400,027	$61,841,225	17
Apr 12, 2024	New	$15,251,730	$10,000,000	4
Jan 13, 2021	New	$50,825,257	$1,075,255	15
Jun 26, 2020	Amendment	$337,500	$337,500	10
Nov 15, 2019	New	$8,000,000	$270,000	10

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Land Therapeutics Inc.

Pharmaceuticals

Offering target: $92,111,706

Filed Oct 20, 2026